Sabrina Serani

This week in oncology highlights: FDA approvals and long-term study results, showcasing advancements in cancer treatments, and patient care strategies.

A novel combination therapy shows high response rates in relapsed DLBCL, enhancing eligibility for autologous stem cell transplantation.

Advancements in cancer care focus on precise detection of measurable residual disease, enhancing monitoring and relapse prediction through innovative technologies and AI integration.

A new platform comprehensively profiles CAR T-cells during manufacturing, revealing phenotypic shifts. This allows for shorter timelines, better outcomes, and personalized therapies.

Lisocabtagene maraleucel led to promising responses in relapsed/refractory marginal zone lymphoma, offering a new option with manageable safety.

Catch up on the week's latest oncology news, from clinical trial updates to FDA approvals.

Taletrectinib emerges as a groundbreaking treatment for ROS1-mutant NSCLC, offering hope with its CNS activity and lower neurological side effects.

The FDA has approved a tablet version of zanubrutinib for all indications, improving convenience and reducing pill burden for patients with blood cancers.

Taletrectinib gains FDA approval as a groundbreaking treatment for ROS1-positive non-small cell lung cancer, offering hope for patients with CNS involvement.

A groundbreaking trial explores pembrolizumab's role in enhancing treatment outcomes for advanced head and neck cancer, promising significant advancements in patient care.

FDA prioritizes review of lurbinectedin and atezolizumab for first-line maintenance therapy in extensive-stage small cell lung cancer, promising improved survival rates.

TuHURA Biosciences advances its phase 3 trial of IFx-2.0 for Merkel cell carcinoma, aiming to enhance immune response alongside pembrolizumab.

A recent study reveals rising early-onset colorectal cancer rates, highlighting disparities and the need for improved screening and early detection strategies.

Cervical cancer prevention advances with new immunotherapy findings, addressing disparities and improving outcomes for underserved women globally.

A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing promising trial results.

Zipalertinib shows promising efficacy and safety for advanced NSCLC with EGFR exon 20 mutations, offering a much-needed oral treatment option.

A groundbreaking study reveals rusfertide's potential to transform polycythemia vera treatment, reducing phlebotomy needs and improving patient quality of life.

Darolutamide is now an FDA-approved treatment option alone or in combination with docetaxel for metastatic castration-sensitive prostate cancer.

Darolutamide significantly delayed pain progression and improved overall well-being in patients with metastatic hormone-sensitive prostate cancer.

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a potential new therapy in the space.

Adjuvant nivolumab offered sustained survival benefits in resected esophageal/GEJ cancer post chemoradiation, with PD-L1 emerging as a potential biomarker.

EBC-129 has been granted FDA fast track designation for the treatment of pancreatic ductal adenocarcinoma, paving the way for development of this antibody-drug conjugate.

This priority review designation for sevabertinib in previously treated HER2-mutant non–small cell lung cancer is supported by data from the phase 1/2 SOHO-01 study.

A zanubrutinib, venetoclax, and obinutuzumab triplet achieved deep remissions and high undetectable measurable residual disease rates in relapsed CLL.

The EFTISARC-NEO trial of eftilagimod alfa with radiotherapy and pembrolizumab in resectable soft tissue sarcoma achieved its primary end point.